ADVISORY/ICOS to Webcast Annual Meeting of Stockholders And is Scheduled to Participate in Upcoming Conference.Business Editors/Health/Medical Writers ADVISORY...For Friday (May 02) BOTHELL, Wash.--(BUSINESS WIRE)--April 24, 2003 ICOS Corporation (Nasdaq:ICOS) announced today that it will webcast its Annual Meeting of Stockholders on May 2, 2003 and participate in the Ragen Mackenzie Investment Conference on May 8, 2003. -0-
ICOS Corporation's Annual Meeting of Stockholders
Date: May 2, 2003
Times: 12:30 p.m. EDT
Speakers: ICOS Corporation Management
After the transaction of formal business at the meeting,
management will provide an update on ICOS' progress and respond
to questions from stockholders.
A webcast of the meeting will be available in real-time and a
replay will be available through May 9, 2003. The webcast can be
accessed through the ICOS website, www.icos.com, Investor -
Events section.
Ragen MacKenzie Investment Conference Presentation
Date: May 8, 2003
Time: 12:30 p.m. EDT
Speaker: David A. Goodkin, M.D., VP, Development and
Chief Medical Officer
A webcast of this ICOS presentation will be available in
real-time and a replay will be available through May 15, 2003.
The webcast can be accessed through the ICOS website,
www.icos.com, Investor - Events section
Additional information on ICOS, including past press releases, is available at www.icos.com. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology Structural biology is a branch of molecular biology concerned with the study of the architecture and shape of biological macromolecules—proteins and nucleic acids in particular—and what causes them to have the structures they have. , high throughput drug screening, medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. and gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. and other urologic disorders, sepsis Sepsis Definition Sepsis refers to a bacterial infection in the bloodstream or body tissues. This is a very broad term covering the presence of many types of microscopic disease-causing organisms. , psoriasis and other inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risks detailed in ICOS' latest Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and its other SEC filings. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion